Literature DB >> 19428222

Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.

Giuseppe Blasi1, Teresa Popolizio, Paolo Taurisano, Grazia Caforio, Raffaella Romano, Annabella Di Giorgio, Fabio Sambataro, Valeria Rubino, Valeria Latorre, Luciana Lo Bianco, Leonardo Fazio, Marcello Nardini, Daniel R Weinberger, Alessandro Bertolino.   

Abstract

Earlier imaging studies in schizophrenia have reported abnormal amygdala and prefrontal cortex activity during emotion processing. We investigated with functional magnetic resonance imaging (fMRI) during emotion processing changes in activity of the amygdala and of prefrontal cortex in patients with schizophrenia during 8 weeks of olanzapine treatment. Twelve previously drug-free/naive patients with schizophrenia were treated with olanzapine for 8 weeks and underwent two fMRI scans after 4 and 8 weeks of treatment during implicit and explicit emotional processing. Twelve healthy subjects were also scanned twice to control for potential repetition effects. Results showed a diagnosis by time interaction in left amygdala and a diagnosis by time by task interaction in right ventrolateral prefrontal cortex. In particular, activity in left amygdala was greater in patients than in controls at the first scan during both explicit and implicit processing, while it was lower in patients at the second relative to the first scan. Furthermore, during implicit processing, right ventrolateral prefrontal cortex activity was lower in patients than controls at the first scan, while it was greater in patients at the second relative to the first scan. These results suggest that longitudinal treatment with olanzapine may be associated with specific changes in activity of the amygdala and prefrontal cortex during emotional processing in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428222      PMCID: PMC2736305          DOI: 10.1016/j.pscychresns.2008.09.001

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  66 in total

1.  Functional disconnections in the direct and indirect amygdala pathways for fear processing in schizophrenia.

Authors:  Pritha Das; Andrew H Kemp; Gary Flynn; Anthony W F Harris; Belinda J Liddell; Thomas J Whitford; Anthony Peduto; Evian Gordon; Leanne M Williams
Journal:  Schizophr Res       Date:  2007-01-10       Impact factor: 4.939

2.  Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia.

Authors:  Robert Christian Wolf; Nenad Vasic; Annett Höse; Manfred Spitzer; Henrik Walter
Journal:  Schizophr Res       Date:  2007-01-26       Impact factor: 4.939

3.  Neural responses to dynamic expressions of fear in schizophrenia.

Authors:  T A Russell; E Reynaud; K Kucharska-Pietura; C Ecker; P J Benson; F Zelaya; V Giampietro; M Brammer; A David; M L Phillips
Journal:  Neuropsychologia       Date:  2006-06-30       Impact factor: 3.139

4.  Emotional words induce enhanced brain activity in schizophrenic patients with auditory hallucinations.

Authors:  Julio Sanjuan; Juan J Lull; Eduardo J Aguilar; Luis Martí-Bonmatí; David Moratal; José C Gonzalez; Montserrat Robles; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2006-12-20       Impact factor: 3.222

5.  Effects of acute antipsychotic treatment on brain activation in first episode psychosis: an fMRI study.

Authors:  P Fusar-Poli; M R Broome; P Matthiasson; S C R Williams; M Brammer; P K McGuire
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-02       Impact factor: 4.600

6.  Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation.

Authors:  E M Meisenzahl; J Scheuerecker; M Zipse; S Ufer; M Wiesmann; T Frodl; N Koutsouleris; T Zetzsche; G Schmitt; M Riedel; I Spellmann; S Dehning; J Linn; H Brückmann; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-06       Impact factor: 5.270

Review 7.  Social brain dysfunctions in schizophrenia: a review of neuroimaging studies.

Authors:  Eric Brunet-Gouet; Jean Decety
Journal:  Psychiatry Res       Date:  2006-11-07       Impact factor: 3.222

8.  Fronto-limbic and autonomic disjunctions to negative emotion distinguish schizophrenia subtypes.

Authors:  Leanne M Williams; Pritha Das; Belinda J Liddell; Gloria Olivieri; Anthony S Peduto; Anthony S David; Evian Gordon; Anthony W F Harris
Journal:  Psychiatry Res       Date:  2007-03-30       Impact factor: 3.222

9.  Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study.

Authors:  Yoshitaka Kumakura; Paul Cumming; Ingo Vernaleken; Hans-Georg Buchholz; Thomas Siessmeier; Andreas Heinz; Thorsten Kienast; Peter Bartenstein; Gerhard Gründer
Journal:  J Neurosci       Date:  2007-07-25       Impact factor: 6.167

Review 10.  Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?

Authors:  Steven R Laviolette
Journal:  Schizophr Bull       Date:  2007-05-22       Impact factor: 9.306

View more
  28 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

2.  Amygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studies.

Authors:  Alan Anticevic; Jared X Van Snellenberg; Rachel E Cohen; Grega Repovs; Erin C Dowd; Deanna M Barch
Journal:  Schizophr Bull       Date:  2010-12-01       Impact factor: 9.306

3.  Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder.

Authors:  Izelle Labuschagne; K Luan Phan; Amanda Wood; Mike Angstadt; Phyllis Chua; Markus Heinrichs; Julie C Stout; Pradeep J Nathan
Journal:  Neuropsychopharmacology       Date:  2010-08-18       Impact factor: 7.853

4.  Limbic activity in antipsychotic naïve first-episode psychotic subjects during facial emotion discrimination.

Authors:  Daniel Bergé; Susanna Carmona; Purificación Salgado; Mariana Rovira; Antoni Bulbena; Oscar Vilarroya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11-21       Impact factor: 5.270

Review 5.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

6.  Emotion effects on attention, amygdala activation, and functional connectivity in schizophrenia.

Authors:  Alan Anticevic; Grega Repovs; Deanna M Barch
Journal:  Schizophr Bull       Date:  2011-03-17       Impact factor: 9.306

Review 7.  Converging effects of diverse treatment modalities on frontal cortex in schizophrenia: A review of longitudinal functional magnetic resonance imaging studies.

Authors:  Ayse Sakalli Kani; Ann K Shinn; Kathryn E Lewandowski; Dost Öngür
Journal:  J Psychiatr Res       Date:  2016-10-19       Impact factor: 4.791

Review 8.  Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations.

Authors:  C C Abbott; A Jaramillo; C E Wilcox; D A Hamilton
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

9.  Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.

Authors:  Fabio Sambataro; Giuseppe Blasi; Leonardo Fazio; Grazia Caforio; Paolo Taurisano; Raffaella Romano; Annabella Di Giorgio; Barbara Gelao; Luciana Lo Bianco; Apostolos Papazacharias; Teresa Popolizio; Marcello Nardini; Alessandro Bertolino
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

10.  Association of Age at Onset and Longitudinal Course of Prefrontal Function in Youth With Schizophrenia.

Authors:  Tara A Niendam; Kimberly L Ray; Ana-Maria Iosif; Tyler A Lesh; Stefania R Ashby; Pooja K Patel; Jason Smucny; Emilio Ferrer; Marjorie Solomon; J Daniel Ragland; Cameron S Carter
Journal:  JAMA Psychiatry       Date:  2018-12-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.